NutriBand Inc. amended its promissory note with TII Jet Services for a $5 million credit line at 7% annual interest, with funds designated for FDA submission and Kindeva manufacturing costs. The facility matures July 1, 2029, and provides working capital flexibility for the company's drug commercialization efforts.